Formulation White Papers & Case Studies

31. Optimize Time, Space and Cost With Inline Buffer Formulation And System 4/7/2026

    Discover how integrating inline buffer formulation with chromatography reduces buffer waste by 50% and delivers a 710% ROI, transforming downstream efficiency and sustainability.

32. Flexibility In Drug Development: From Tactical Response To Strategic Imperative 4/6/2026

    Build flexibility into your drug development strategy to navigate change effectively, maintain momentum, and drive successful outcomes across every stage of the lifecycle.

33. Early-Phase Injectable Formulation Development 4/6/2026

    Discover how expert-driven strategies and data-centric tools can help you overcome formulation challenges and accelerate the development of stable, high-performance injectable therapeutics.

34. The Effect Of Conventional Cooling Versus Controlled Ice Nucleation On Primary Drying Time 4/1/2026

    See how controlled ice nucleation shortens lyophilization cycles, supports higher drying temperatures, and reduces complexity for amorphous and mixed formulations without sacrificing quality.

35. WuXiHigh 2.0 Delivers A 180 mg/mL Formula 3/26/2026

    This case study shows how smart formulation and integrated development achieved a stable 180 mg/mL biologic for subcutaneous delivery, for teams tackling concentration issues.

36. Tailoring Viral Clearance Study Design 3/4/2026

    Viral‑clearance studies need phase‑appropriate design, strong virus stocks, modality‑specific risk assessment, and alignment with evolving regulations for reliable safety outcomes.

37. Complementary Methodologies For Analysis Of NISTmAb Impurities 2/27/2026

    Gain insight into how SEC and CE‑SDS complement each other to assess monoclonal antibody size variants, offering stronger insight into aggregates, fragments, and overall purity.

38. A Journey To Produce MSC-Derived Cell Therapies From Isolation To Large-Scale 2/26/2026

    Drive successful MSC therapy development by optimizing isolation methods, surface chemistry, and closed-system expansion technologies to ensure cellular stability and commercial scalability.

39. De-Risking Glycosylation: Scaling In Vitro Glycoengineering From Lab To GMP 2/13/2026

    Access a phased, risk-minimized integration framework to scale your enzymatic post-production process seamlessly from initial lab-scale feasibility up to commercial GMP readiness.

40. Levers To Optimize The IVT Reaction For Increased mRNA Yield 2/10/2026

    Mastering IVT yield requires balancing magnesium and nucleotide ratios. Learn how specific buffers and pyrophosphatase optimize mRNA synthesis for scalable, high-quality therapeutic production.